GB202217507D0 - Natural killer cells - Google Patents
Natural killer cellsInfo
- Publication number
- GB202217507D0 GB202217507D0 GBGB2217507.9A GB202217507A GB202217507D0 GB 202217507 D0 GB202217507 D0 GB 202217507D0 GB 202217507 A GB202217507 A GB 202217507A GB 202217507 D0 GB202217507 D0 GB 202217507D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- natural killer
- killer cells
- cells
- natural
- killer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2307—Interleukin-7 (IL-7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/42—Notch; Delta; Jagged; Serrate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2217507.9A GB202217507D0 (en) | 2022-11-23 | 2022-11-23 | Natural killer cells |
| CN202380091964.9A CN120693400A (en) | 2022-11-23 | 2023-11-23 | Natural killer cells |
| PCT/GB2023/053061 WO2024110758A2 (en) | 2022-11-23 | 2023-11-23 | Natural killer cells |
| EP23817198.7A EP4623071A2 (en) | 2022-11-23 | 2023-11-23 | Natural killer cells |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2217507.9A GB202217507D0 (en) | 2022-11-23 | 2022-11-23 | Natural killer cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB202217507D0 true GB202217507D0 (en) | 2023-01-04 |
Family
ID=84889026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB2217507.9A Ceased GB202217507D0 (en) | 2022-11-23 | 2022-11-23 | Natural killer cells |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4623071A2 (en) |
| CN (1) | CN120693400A (en) |
| GB (1) | GB202217507D0 (en) |
| WO (1) | WO2024110758A2 (en) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK34086A (en) * | 1985-01-23 | 1986-07-24 | Abbott Lab | PEPTIDYLAMINODIOLS |
| CA2023099A1 (en) * | 1989-09-04 | 1991-03-05 | Quirico Branca | Amino acid derivatives |
| CN101560184A (en) * | 2008-04-16 | 2009-10-21 | 中国科学院成都生物研究所 | N-chiral quaternary ammonium salt derived from amino acid and preparation method thereof |
| WO2011022619A1 (en) * | 2009-08-20 | 2011-02-24 | Glaxo Group Limited | TREATING INFLAMMATORY DISEASES BY ADMINISTRATION OF REV-ERB α LIGANDS |
| CA2830080C (en) * | 2011-03-18 | 2021-10-26 | Jan Spanholtz | Generation of nk cells and nk-cell progenitors |
| WO2013033310A1 (en) | 2011-08-31 | 2013-03-07 | Theodore Mark Kamenecka | Modulators of rev-erb |
| US9872851B2 (en) * | 2012-12-12 | 2018-01-23 | The Charlotte-Mecklenburg Hospital Authority | Methods of treating portal hypertension |
| US9750718B2 (en) * | 2012-12-12 | 2017-09-05 | The Charlotte-Mecklenburg Hospital Authority | Methods of treating hepatic fibrosis and associated diseases by regulating Rev-ERB activity |
| WO2015103527A1 (en) | 2014-01-06 | 2015-07-09 | The Scripps Research Institute | Modulators of rev-erb |
| WO2018148531A1 (en) * | 2017-02-10 | 2018-08-16 | Case Western Reseve University | Compositions and methods of treating cardiac hypertrophy and heart failure |
| GB201704953D0 (en) * | 2017-03-28 | 2017-05-10 | Imp Innovations Ltd | Natural killer cells |
| GB201810486D0 (en) | 2018-06-26 | 2018-08-08 | Imperial Innovations Ltd | Natural killer cells |
| US11845724B2 (en) * | 2019-09-11 | 2023-12-19 | Vincere Biosciences, Inc. | USP30 inhibitors and uses thereof |
-
2022
- 2022-11-23 GB GBGB2217507.9A patent/GB202217507D0/en not_active Ceased
-
2023
- 2023-11-23 WO PCT/GB2023/053061 patent/WO2024110758A2/en not_active Ceased
- 2023-11-23 CN CN202380091964.9A patent/CN120693400A/en active Pending
- 2023-11-23 EP EP23817198.7A patent/EP4623071A2/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN120693400A (en) | 2025-09-23 |
| EP4623071A2 (en) | 2025-10-01 |
| WO2024110758A3 (en) | 2025-01-02 |
| WO2024110758A2 (en) | 2024-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL285543A (en) | Natural killer cells modified for immunotherapy | |
| GB201810486D0 (en) | Natural killer cells | |
| IL277467A (en) | Method for producing natural killer cells | |
| GB202007321D0 (en) | T cells | |
| GB2614815B (en) | Cell Culture Construct | |
| ZA202211411B (en) | Cell | |
| IL324321A (en) | Multi-receptor natural killer cells | |
| IL276374A (en) | Transforming growth factor beta-resistant natural killer cells | |
| GB202209920D0 (en) | Cell | |
| SG11202104662UA (en) | Method for culturing cord blood-derived natural killer cells using transformed t-cells | |
| GB202214410D0 (en) | genetically modified cells | |
| GB202217507D0 (en) | Natural killer cells | |
| GB202212838D0 (en) | Natural killer cells | |
| IL311786A (en) | Hypoimmune cells | |
| IL324320A (en) | Multi-receptor natural killer cells | |
| GB202319587D0 (en) | Invariant natural killer T cell | |
| GB202316722D0 (en) | Invariant natural killer t cell | |
| CA3275046A1 (en) | Natural killer cell engagers | |
| GB202002073D0 (en) | Horizontal cells | |
| CA3290740A1 (en) | Multi-receptor natural killer cells | |
| GB202307766D0 (en) | Cell | |
| GB202306619D0 (en) | Cell | |
| GB2636141B (en) | Cell selection | |
| GB202217050D0 (en) | Cell rejuvination | |
| GB202219164D0 (en) | Modified T cells |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |